+1-888-308-5802     
News Contact Us

Glenmark & Harbour BioMed team up, develop cancer antibodies in China

Author : Saipriya Iyer | Published Date : 2018-08-08 

Mumbai-based Glenmark Pharmaceuticals has reportedly announced an exclusive license agreement with China-based Harbour BioMed. The deal, worth more than $120 million, showcases China’s willingness to transform healthcare by encouraging innovation.

Sources cite that the agreement aims at developing, producing & commercializing Glenmark’s GBR 1302 drug for the greater China region where the prevalence of certain HER2 positive cancer cases generates a clinical need.

A press release by Glenmark Pharma states that the GBR 1302 is a part of Glenmark’s patented BEAT platform and is a bispecific antibody that targets CD3 & HER2. It is utilized for the treatment of HER2 positive cancers. The drug is reportedly undergoing enrollment in the U.S. & Germany, and works by stimulating the immune system to fight against the HER2 overexpressing tumor cells.

The company would receive an upfront payment and payments on achieving certain development level, commercial & regulatory milestones, tiered royalties from Harbour BioMed on product sales.

Glenmark Chairman and MD, Glenn Saldanha expressed his delight about establishing this strategic relationship with Harbour BioMed whose extensive local experience will aid Glenmark in discovering, developing & innovating drugs for certain unfulfilled medical needs.

Harbour BioMed Founder & CEO, Dr. Jingsong Wang stated that this partnership aligns with their plan of leveraging company’s expertise in clinical development by in-licensing innovative clinical-stage products. He further added that the GBR 1302 compliments their internal portfolio of innovative antibody therapeutics.

Glenmark President and Chief Scientific Officer, Kurt Stoeckli stated that both companies follow the same principles and possess a common vision of developing highly effective & precise medicines to help cancer patients. He added that they look forward to achieving this goal together.

Post the announcement, Glenmark Pharma started trading 0.91% higher at about Rs. 602 per share, cite trusted sources.

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Discord gaming app to become a general-purpose communications platform

Published Date: 2020-07-02         Author: Saipriya Iyer

Discord application, which was originally launched with a focus on video games, has reportedly announced that it is planning to emerge into a more general-purpose communications platform. Jason Citron, the Founder and CEO of Discord, has stated that the company’s original branding did not s... Read More

Amazon to offer 20,000 temporary or seasonal employment opportunities

Published Date: 2020-06-29         Author: Saipriya Iyer

Amazon has recently stated that it will offer nearly 20,000 temporary or seasonal employment opportunities in its CS (customer service) organization. This will enable the company to offer a seamless shopping experience for users in India and across the globe. These temporary job opportunities wer... Read More

Singtel & StarHub choose Ericsson & Nokia as 5G network providers

Published Date: 2020-06-26         Author: Saipriya Iyer

Telecommunication operators in Singapore have reportedly chosen Ericsson AB & Nokia Oyj as the main 5G network providers. This has led Huawei Technologies Co. to have less significant contracts in the region. Singapore Telecommunications Limited has chosen Ericsson as its main 5G provider, wh... Read More

© 2020 Fractovia. All Rights Reserved